SCHEMBL10326481

SCHEMBL10326481

CC(C)C1Nc2ccccc2NC1=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CREBBP Q92793 4/20 0.58
BRPF1 P55201 1/20 0.58
GAA P10253 6/20 0.47
THRB P10828 2/20 0.47
KDM4E B2RXH2 6/20 0.46
ALDH1A1 P00352 5/20 0.46
BRD4 O60885 4/20 0.44
EP300 Q09472 1/20 0.44
ALOX15 P16050 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
HSD17B10 Q99714 2/20 0.43
MAPT P10636 3/20 0.41
MEN1 O00255 2/20 0.41
RAB9A P51151 2/20 0.41
KMT2A Q03164 2/20 0.41
NPC1 O15118 1/20 0.41
TP53 P04637 1/20 0.41
HPGD P15428 1/20 0.41
MAPK1 P28482 1/20 0.41
PARP1 P09874 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10326971 1.00 CREBBP (0.58) CREBBPBRPF1GAATHRBKDM4E
SCHEMBL31689232 1.00 CREBBP (0.58) CREBBPBRPF1GAATHRBKDM4E
SCHEMBL17677004 1.00 CREBBP (0.58) CREBBPBRPF1GAATHRBKDM4E
SCHEMBL31689221 0.82 CREBBP (0.51) CREBBPBRPF1GAATHRBKDM4E
SCHEMBL10326493 0.82 CREBBP (0.51) CREBBPBRPF1GAATHRBKDM4E
SCHEMBL10326919 0.82 CREBBP (0.51) CREBBPBRPF1GAATHRBKDM4E
SCHEMBL17676990 0.82 CREBBP (0.51) CREBBPBRPF1GAATHRBKDM4E
SCHEMBL30634601 0.82 CREBBP (0.51) CREBBPBRPF1GAATHRBKDM4E
SCHEMBL17676998 0.82 CREBBP (0.51) CREBBPBRPF1GAATHRBKDM4E
SCHEMBL6696981 0.81 CREBBP (0.50) CREBBPBRPF1GAATHRBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023215367-A1 BICYCLIC PIPERAZINONES AND THERAPEUTIC USES THEREOF CYTOKINETICS, INC. (US) 2023-11-09 WO disclosed
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-20220402896-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2022-12-22 US disclosed
US-11312704-B2 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2022-04-26 US disclosed
US-20210355111-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2021-11-18 US disclosed
US-11174231-B1 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2021-11-16 US disclosed
US-11124497-B1 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2021-09-21 US disclosed
EP-2438989-B1 USE OF ASYMMETRIC HYDROGENATION CATALYST TAKASAGO PERFUMERY CO LTD (JP) 2016-04-13 EP disclosed
US-8217204-B2 Catalyst for asymmetric hydrogenation TAKASAGO INTERNATIONAL CORPORATION (JP) 2012-07-10 US disclosed
US-20100324338-A1 CATALYST FOR ASYMMETRIC HYDROGENATION TAKASAGO INTERNATIONAL CORPORATION (JP) 2010-12-23 US disclosed
WO-2010140636-A1 ASYMMETRIC HYDROGENATION CATALYST 高砂香料工業株式会社 (JP) 2010-12-09 WO disclosed
WO-2010075542-A1 CDK INHIBITORS CURIS, INC. (US) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324338-A1 CATALYST FOR ASYMMETRIC HYDROGENATION H1-0, H1-5, ADH5 CREBBP 1410/4885BRPF1 4135/4885GAA 1498/4885
US-11312704-B2 Inhibitors of cysteine proteases and methods of use thereof CTSV, CTRL, CTSL CREBBP 2433/4885BRPF1 3332/4885GAA 329/4885
US-20220402896-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTSV, CTRL, CTSL CREBBP 2433/4885BRPF1 3332/4885GAA 329/4885
US-20210355111-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSV, CTSL CREBBP 2077/4885BRPF1 2657/4885GAA 363/4885
US-11124497-B1 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL CREBBP 2290/4885BRPF1 2405/4885GAA 447/4885
US-11174231-B1 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL CREBBP 2077/4885BRPF1 2657/4885GAA 363/4885
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV CREBBP 2437/4885BRPF1 3215/4885GAA 326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.